American Society of Hematology

SHERPA: Blue

People

  1. Salles
    Salles
  2. Palomba
    Palomba
  3. Zelenetz
    Zelenetz
  4. Falchi
    Falchi
  5. Kumar
    Kumar
  6. Hamlin
    Hamlin
  7. Moskowitz
    Moskowitz
  8. Lue
    Lue
  9. Noy
    Noy
  10. Shah
    Shah

Groups

  1. Department of Medicine (145)
  2. Hematologic Malignancies, Division of (145)
  3. Center for Hematologic Malignancies (98)
  4. Lymphoma (96)
  5. Hematology-Oncology Fellows (83)
  6. Graduate Medical Education (65)
  7. Survivorship Research (61)
  8. GME, Medicine (59)
  9. Sloan Kettering Institute Postdocs (57)
  10. Epidemiology and Biostatistics (52)
Search Within
  1. "Gilles Salles"
Formats
  1. Meeting Abstract (116)
  2. Journal Article (21)
  3. Research Letter (5)
  4. Review (2)
  5. Guidelines (1)
Groups
  1. Department of Medicine (145)
  2. Hematologic Malignancies, Division of (145)
  3. Center for Hematologic Malignancies (98)
  4. Lymphoma (96)
  5. Hematology-Oncology Fellows (83)
  6. Graduate Medical Education (65)

More Groups

People
  1. Gilles Salles (145)
  2. Maria Palomba (67)
  3. Andrew Zelenetz (52)
  4. Lorenzo Falchi (46)
  5. Anita Kumar (43)
  6. Paul Hamlin (38)

More People

Years
  1. 2025 (6)
  2. 2024 (38)
  3. 2023 (43)
  4. 2022 (35)
  5. 2021 (17)
  6. 2020 (6)
Publications
  1. Blood (127)
  2. Blood Advances (17)
  3. Hematology-American Society of Hematology Education Program (1)

Results (145)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants
    Journal Article

    Ghione, P.; Mandelker, D.; Arcila, M.; Seshan, V.; Terry, M. B.; Vijai, J.; Cordeiro, P.; Vanderbilt, C.; Pressley, J.; Chan, A.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • T-ICAHT: Grading and prognostic impact of thrombocytopenia after CAR T-cell therapy
    Journal Article

    Rejeski, K.; Sanz, J.; Fei, T.; Nair, M. S.; Hashmi, H.; Avigdor, A.; Beyar-Katz, O.; Bücklein, V. L.; Curran, K. J.; Einarsdottir, S.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes
    Research Letter

    Trněný, M.; Fogliatto, L.; Gardner, F.; Flinn, I.; Larouche, J. F.; Haioun, C.; Canales, M.; Goto, H.; Hajek, R.; Salles, G.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
    Journal Article

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chhabra, S.; Chabowska, M.; Dogan, A.; Falchi, L.; Grieve, C.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • The current landscape of frontline large B-cell lymphoma trials
    Review

    Qualls, D.; Armand, P.; Salles, G.
    Blood (2025)

    Fulltext@MSK | Save
  • Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
    Journal Article

    Valtis, Y. K.; Devlin, S.; Shouval, R.; Rejeski, K.; Corona, M.; De Abia, A. L.; Rivas-Delgado, A.; Luttwak, E.; Cassanello, G.; Landego, I.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Phase 3, randomized, open-label study of epcoritamab plus lenalidomide compared with rituximab plus gemcitabine and oxaliplatin in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Ozcan, M.; Kim, W. S.; Zhang, H.; Bouzani, M.; Nagy, Z.; Chuah, H.; Salles, G.; Jeng, E. E.; Huang, J.; Sacchi, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparison of progression-free survival of relapsed or refractory follicular lymphoma patients in a single-arm trial of tazemetostat with a real-world external control arm
    Meeting Abstract

    Salles, G.; Leonard, J. P.; Morschhauser, F.; Crowley, A.; Sosinsky, A. Z.; Lieb, C.; Zeldow, B.; Harton, J.; Wang, S.; Boyer, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Rituximab plus /- ibrutinib as first line therapy for marginal zone lymphoma
    Meeting Abstract

    Noy, A.; Thet, W. S.; Vemuri, S.; Seshan, V.; Batlevi, C. L.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Habermann, T. M.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Two decade single institution experience highlights rare survivors with relapsed or refractory Burkitt lymphoma
    Meeting Abstract

    Molla, R.; Berman, E.; Caron, P.; Donnelly, G.; Falchi, L.; Hamlin, P. A.; Horwitz, S.; Intlekofer, A. M.; Johnson, W. T.; Jurcic, J. G.; more...
    Blood (2024)

    Fulltext@MSK | Save